In Brief: Roussel-Uclaf's Nilandron
Executive Summary
Roussel-Uclaf's Nilandron: Nilutamide tablet "approvable" again by FDA Feb. 22 in 50 mg dosage for treatment of prostate cancer. The NDA, filed by Besselaar, was approvable previously on March 7, 1995...